Manufacturer record
R.P. Biotech Pvt. Ltd. 61: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
5 batches manufactured by R.P. Biotech Pvt. Ltd. 61 (Punjab) were declared Not of Standard Quality in September 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 6563, RAXOFEN Ibuprofen and Paracetamol Tablets IP (exp Mar 2027). RDTL, Chandigarh (CDSCO lab) found it not of standard quality: sample does not conform to claim as per IP 2022 in respect to the Test of Dissolution of Paracetamol, Dissolution of Ibuprofen. Listed in the September 2025 alert.
Records by type
5 records linked to R.P. Biotech Pvt. Ltd. 61 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| RAXOFEN Ibuprofen and Paracetamol Tablets IP | Batch 6563Mfg Apr 2025 · Exp Mar 2027 | sample does not conform to claim as per IP 2022 in respect to the Test of Dissolution of Paracetamol, Dissolution of IbuprofenDissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| PANZOLE Pantoprazole Sodium Tablets I.P. | Batch 6735Mfg Jun 2025 · Exp May 2027 | sample does not conform to claim as per IP 2022 and Addendum 2024 in respect to the Test of Dissolution (Buffer Stage)Dissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| Loperamide Hydrochloride Capsules IP 2 mg | Batch 7645Mfg Mar 2025 · Exp Feb 2027 | sample does not conform to claim as per IP 2022 in respect to the Test of DissolutionDissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| Cyproheptadine Tablets IP 4 mg | Batch 6489Mfg Mar 2025 · Exp Feb 2027 | sample does not conform to claim as per IP 2022 in respect to the Assay of Cyproheptadine HydrochlorideAssay | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| AMLOCARE-AT Amlodipine and Atenolol Tablets IP | Batch 6717Mfg Jun 2025 · Exp May 2027 | sample does not conform to claim as per IP 2022 in respect to the Assay of Amlodipine Besylate Calculated As Amlodipine, AtenololAssay | RDTL, ChandigarhCDSCO lab | Sep 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.